Literature DB >> 29570178

Predictors of Intravenous Immunoglobulin Nonresponse and Racial Disparities in Kawasaki Disease.

Daniel E Clark1, Kara J Denby1, Laura M Kaufman2, Mary-Margaret A Fill3, Bhinnata Piya4, Shanthi Krishnaswami4, Christopher Fonnesbeck5, Natasha Halasa4.   

Abstract

BACKGROUND: Kawasaki disease (KD) is the most common cause of acquired heart disease in American children. Intravenous immunoglobulin (IVIG) nonresponse is a known risk factor for cardiac sequelae. Previously reported risk factors for nonresponse include age, male sex and laboratory abnormalities. We set out to identify additional risk factors for IVIG nonresponse in a racially diverse KD population.
METHODS: We conducted a retrospective chart review at a referral center in the Southeastern United States of children meeting ICD-9 (International Statistical Classification of Disease and Related Health Problems) criteria for KD and being treated with IVIG.
RESULTS: Four-hundred and fifty-nine children met inclusion criteria, 67 were excluded for subsequent rheumatologic diagnosis, unknown race, or failure to meet the American Heart Association guideline criteria. Our final cohort consisted of 392 subjects, with median age of 2.7 years, 65.1% male, 66.1% White, 24.2% Black, 4.9% Asian and 82.9% responded to a single dose of IVIG. Coronary ectasia or aneurysm developed in 27%; 7.4% developed aneurysms and 2.3% giant coronary aneurysms. Nonresponders were more likely to be Black, have higher white blood cell, erythrocyte sedimentation rate and C-reactive protein, lower hemoglobin, develop ectasia or aneurysm and require critical care and hospital readmission. Responders achieved echocardiographic normalization more often compared with nonresponders (81.3% vs. 60.9%, P = 0.002) and coronary artery pseudonormalization (87.2% vs. 69.7%, P = 0.03) at 1 year. Black nonresponders had the slowest normalization at 1 year (52.9%, P = 0.02).
CONCLUSIONS: Nonresponders have higher rates and greater severity of coronary involvement than responders. Our study uniquely demonstrates Black race as a risk factor for nonresponse and for delayed normalization of cardiac involvement at 1-year follow-up.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29570178     DOI: 10.1097/INF.0000000000002019

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  8 in total

1.  The factors affecting the disease course in Kawasaki disease.

Authors:  Elif Arslanoglu Aydin; Ilker Ertugrul; Yelda Bilginer; Ezgi Deniz Batu; Hafize Emine Sonmez; Selcan Demir; Zehra Serap Arici; Erdal Sag; Dursun Alehan; Seza Ozen
Journal:  Rheumatol Int       Date:  2019-05-28       Impact factor: 2.631

2.  Etanercept With IVIg for Acute Kawasaki Disease: A Randomized Controlled Trial.

Authors:  Michael A Portman; Nagib S Dahdah; April Slee; Aaron K Olson; Nadine F Choueiter; Brian D Soriano; Sujatha Buddhe; Carolyn A Altman
Journal:  Pediatrics       Date:  2019-05-02       Impact factor: 7.124

3.  [Association of liver damage with coronary artery lesion and no response to intravenous immunoglobulin in the acute stage of Kawasaki disease].

Authors:  Hui-Min Hu; Xiao-Zheng Chen; Yong-Lan Zhang; Zhong-Dong DU
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-06-15

4.  Evaluating the time-varying risk of hypertension, cardiac events, and mortality following Kawasaki disease diagnosis.

Authors:  Jennifer J Y Lee; Brian M Feldman; Brian W McCrindle; Ping Li; Rae Sm Yeung; Jessica Widdifield
Journal:  Pediatr Res       Date:  2022-08-24       Impact factor: 3.953

5.  Risk Model Development and Validation for Prediction of Coronary Artery Aneurysms in Kawasaki Disease in a North American Population.

Authors:  Mary Beth F Son; Kimberlee Gauvreau; Adriana H Tremoulet; Mindy Lo; Annette L Baker; Sarah de Ferranti; Fatma Dedeoglu; Robert P Sundel; Kevin G Friedman; Jane C Burns; Jane W Newburger
Journal:  J Am Heart Assoc       Date:  2019-06-04       Impact factor: 5.501

6.  Is there an association between intravenous immunoglobulin resistance and coronary artery lesion in Kawasaki disease?-Current evidence based on a meta-analysis.

Authors:  Xiaolan Zheng; Jinhui Li; Peng Yue; Lei Liu; Jiawen Li; Kaiyu Zhou; Yimin Hua; Yifei Li
Journal:  PLoS One       Date:  2021-03-25       Impact factor: 3.240

7.  Defining the risk of first intravenous immunoglobulin unresponsiveness in non-Asian patients with Kawasaki disease.

Authors:  Maryam Piram; Martha Darce Bello; Stéphanie Tellier; Sylvie Di Filippo; Franck Boralevi; Fouad Madhi; Ulrich Meinzer; Rolando Cimaz; Celine Piedvache; Isabelle Koné-Paut
Journal:  Sci Rep       Date:  2020-02-20       Impact factor: 4.379

8.  Kawasaki Disease and Clinical Outcome Disparities Among Black Children.

Authors:  Luz A Padilla; Jacqueline L Collins; Adeniyi J Idigo; Yung Lau; Michael A Portman; Sadeep Shrestha
Journal:  J Pediatr       Date:  2020-09-24       Impact factor: 4.406

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.